High Serum Levels of Soluble IL-2 Receptor, Cytokines, and C Reactive Protein Correlate with Impairment of T Cell Response in Patients with Advanced Epithelial Ovarian Cancer

This publication has 37 references indexed in Scilit:

• Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer
  Cancer, 1994
• IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-α and β (lymphotoxin)
  Cytokine, 1992
• Cytokines and Their Role in the Pathophysiology of Cancer Cachexia
  Journal of Parenteral and Enteral Nutrition, 1992
• Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
  Journal of Clinical Investigation, 1992
• Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6
  Hepatology, 1990
• Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation
  Cancer Immunology, Immunotherapy, 1989
• Immunological Control of Tumor Metastases
  Published by Springer Nature ,1989
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Interleukin-1 and the Pathogenesis of the Acute-Phase Response
  New England Journal of Medicine, 1984
• Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease.
  Journal of Clinical Pathology, 1983